| P2093 | author name string | Schwarz M | |
| | Muller N | |
| P2860 | cites work | Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects | Q22248075 |
| | Is schizophrenia a neurodevelopmental disorder? | Q22337044 |
| | Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types | Q24310976 |
| | Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation | Q24338135 |
| | Association of neuregulin 1 with schizophrenia confirmed in a Scottish population | Q24561773 |
| | Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia | Q24612644 |
| | Neuregulin 1 and susceptibility to schizophrenia | Q24616921 |
| | Viruses, schizophrenia, and bipolar disorder | Q24669648 |
| | Regulation of prostaglandin synthesis and cell adhesion by a tryptophan catabolizing enzyme | Q24798233 |
| | Heritability estimates for psychotic disorders: the Maudsley twin psychosis series | Q28137629 |
| | M-1/M-2 macrophages and the Th1/Th2 paradigm | Q28145893 |
| | The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications | Q28188380 |
| | Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies | Q28190066 |
| | Tolerance, DCs and tryptophan: much ado about IDO | Q28203295 |
| | Genetics of susceptibility to human infectious disease | Q28208872 |
| | The NMDA-receptor antagonist CPP abolishes neurogenic 'wind-up pain' after intrathecal administration in humans | Q28243687 |
| | Seasonality of births in schizophrenia and bipolar disorder: a review of the literature | Q28258948 |
| | Kynurenic acid and schizophrenia | Q28267688 |
| | The S100 protein family: history, function, and expression | Q28293937 |
| | Adult schizophrenia following prenatal exposure to an influenza epidemic | Q28296274 |
| | Human microglia convert l-tryptophan into the neurotoxin quinolinic acid | Q28379366 |
| | Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase | Q28507305 |
| | Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia | Q28568230 |
| | Nicotinic receptors regulate B lymphocyte activation and immune response | Q28591391 |
| | Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence | Q29618819 |
| | Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses | Q29618915 |
| | The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia | Q33537860 |
| | Should schizophrenia be treated as a neurocognitive disorder? | Q33693532 |
| | Prostaglandin E(2) increases bovine leukemia virus tax and pol mRNA levels via cyclooxygenase 2: regulation by interleukin-2, interleukin-10, and bovine leukemia virus | Q33806129 |
| | Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes | Q33846443 |
| | Aberrant prostaglandin synthase 2 expression defines an antigen-presenting cell defect for insulin-dependent diabetes mellitus | Q33857220 |
| | Nicotinic receptors in the brain. Links between molecular biology and behavior. | Q33872186 |
| | Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia | Q34059501 |
| | D-serine added to antipsychotics for the treatment of schizophrenia | Q34068005 |
| | Fetal hypoxia and structural brain abnormalities in schizophrenic patients, their siblings, and controls. | Q34108092 |
| | Epidemiology of schizophrenia: the global burden of disease and disability | Q34128570 |
| | The inflammatory reflex | Q34165907 |
| | Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence | Q34192699 |
| | Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London | Q34245156 |
| | Neuregulin and ErbB receptor signaling pathways in the nervous system | Q34278032 |
| | Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial | Q34308081 |
| | Cholinergic systems and schizophrenia: primary pathology or epiphenomena? | Q34318020 |
| | Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia | Q34327777 |
| | Serologic evidence of prenatal influenza in the etiology of schizophrenia | Q34338056 |
| | Schizophrenia and viral infection during neurodevelopment: a focus on mechanisms | Q34416948 |
| | Genetics and genomics in infectious disease susceptibility | Q34426106 |
| | Association between central nervous system infections during childhood and adult onset schizophrenia and other psychoses: a 28-year follow-up | Q34437567 |
| | T-helper-1 and T-helper-2 responses in psychiatric disorders | Q34487625 |
| | Prostaglandins as modulators of immunity | Q34543566 |
| | Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia | Q34707093 |
| | Psychiatric side effects of indomethacin in parturients | Q44491360 |
| | IL-2 and IL-4 polymorphisms as candidate genes in schizophrenia | Q44591382 |
| | Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms | Q44726598 |
| | COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy | Q44780900 |
| | Maternal exposure to bacterial endotoxin during pregnancy enhances amphetamine-induced locomotion and startle responses in adult rat offspring | Q44788107 |
| | Clozapine modulates midbrain dopamine neuron firing via interaction with the NMDA receptor complex | Q44808036 |
| | Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia | Q44824019 |
| | Prenatal exposure to the 1957 influenza epidemic and adult schizophrenia: a follow-up study | Q45022278 |
| | Atypical antipsychotics: matching receptor profile to individual patient's clinical profile | Q45099748 |
| | Clinical effects of COX-2 inhibitors on cognition in schizophrenia. | Q45153924 |
| | Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring | Q45278350 |
| | Activation of noradrenergic locus coeruleus neurons by clozapine and haloperidol: involvement of glutamatergic mechanisms | Q45287107 |
| | Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia | Q46427309 |
| | The cholinergic anti-inflammatory pathway regulates the host response during septic peritonitis | Q46494177 |
| | Muscarinic receptor stimulation reduces NMDA responses in CA3 hippocampal pyramidal cells via Ca2+-dependent activation of tyrosine phosphatase. | Q46580211 |
| | Increased phencyclidine-induced hyperactivity following cortical cholinergic denervation | Q46764174 |
| | Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. | Q46780371 |
| | Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain | Q46933509 |
| | Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. | Q47229546 |
| | Relationship of obstetric complications and differences in size of brain structures in monozygotic twin pairs discordant for schizophrenia | Q47247143 |
| | Increased frequency of CD8 positive gamma/delta T-lymphocytes (CD8+ gamma/delta+) in unmedicated schizophrenic patients: relation to impairment of the blood-brain barrier and HLA-DPA*02011. | Q47741971 |
| | The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. | Q47741981 |
| | Cerebrospinal fluid prostaglandins and corticotropin releasing factor in schizophrenics and controls: relationship to sleep architecture | Q47871278 |
| | Administration of interleukin-1 at birth affects dopaminergic neurons in adult mice | Q47966803 |
| | Interleukin-1, but not stress, stimulates glucocorticoid output during early postnatal life in mice | Q47966816 |
| | S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia | Q48008575 |
| | Schizophrenia, sensory gating, and nicotinic receptors | Q48012124 |
| | Antibodies to infectious agents in individuals with recent onset schizophrenia | Q48021623 |
| | Evidence for activation of microglia in patients with psychiatric illnesses | Q48118772 |
| | Increase in expression of adhesion molecule receptors on T helper cells during antipsychotic treatment and relationship to blood-brain barrier permeability in schizophrenia. | Q48238053 |
| | Clinical and laboratory evidence of autoimmunity in acute schizophrenia | Q48238789 |
| | Identification of tryptophan 2,3-dioxygenase RNA in rodent brain | Q48329961 |
| | On the production and disposition of quinolinic acid in rat brain and liver slices | Q48365939 |
| | Increased arachidonic acid induced platelet chemiluminescence indicates cyclooxygenase overactivity in schizophrenic subjects | Q48457793 |
| | Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients | Q73391432 |
| | [CSF Filtration as Experimental Therapy in Therapyresistant Psychoses in Borna Disease Virus-Seropositive Patients] | Q73401227 |
| | Analysis of a polymorphism in the promoter region of the tumor necrosis factor alpha gene in schizophrenia and bipolar disorder: further support for an association with schizophrenia | Q73729305 |
| | Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission | Q73794171 |
| | Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization | Q73943541 |
| | Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia | Q74225875 |
| | Serum interleukin-18 levels are elevated in schizophrenia | Q74297258 |
| | Potential role for the narcolepsy- and multiple sclerosis-associated HLA allele DQB1*0602 in schizophrenia subtypes | Q74459076 |
| | Immunological and infectious aspects of schizophrenia | Q76390665 |
| | Interleukin-4 and interferon-gamma: the quintessence of a mutual antagonistic relationship | Q77579665 |
| | Antibodies to heat shock proteins in schizophrenic patients: implications for the mechanism of the disease | Q77987854 |
| | 3-Hydroxyanthranilic acid as an intermediate in the oxidation of the indole nucleus of tryptophan | Q79250452 |
| | T- and B-lymphocytes in patients with schizophrenia in acute psychotic episode and the course of the treatment | Q80192507 |
| | ICAM G241A polymorphism and soluble ICAM-1 serum levels: evidence for an active immune process in schizophrenia | Q81498440 |
| | Soluble IL-6 receptors in the serum and cerebrospinal fluid of paranoid schizophrenic patients | Q84447038 |
| | Glutamate receptor dysfunction and schizophrenia | Q34719075 |
| | Acquisition of lymphokine-producing phenotype by CD4+ T cells | Q34724514 |
| | Neuropharmacology of quinolinic and kynurenic acids | Q34728770 |
| | Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia | Q34756417 |
| | Cellular and humoral immune system in schizophrenia: a conceptual re-evaluation | Q35073823 |
| | Management of the negative symptoms of schizophrenia: new treatment options | Q35201017 |
| | Environmental risk factors for psychosis. | Q35236564 |
| | Indomethacin induced psychosis | Q35509787 |
| | The genetics of schizophrenia: glutamate not dopamine? | Q35586653 |
| | Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality | Q35595248 |
| | Childhood meningitis, brain maturation and the risk of psychosis | Q35678419 |
| | S100B in schizophrenic psychosis | Q35684744 |
| | The etiopathogenesis of schizophrenias | Q35951559 |
| | Psychotropic effects of COX-2 inhibitors--a possible new approach for the treatment of psychiatric disorders | Q35954407 |
| | Cortical cholinergic transmission and cortical information processing in schizophrenia | Q36124290 |
| | Negative association between schizophrenia and rheumatoid arthritis | Q37021708 |
| | Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2. | Q37608027 |
| | Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia | Q37698891 |
| | Maternal infections and subsequent psychosis among offspring. | Q37872951 |
| | Antipsychotic drugs, neurotransmitters, and schizophrenia | Q39180903 |
| | The current status of the dopamine hypothesis of schizophrenia | Q39577491 |
| | Biology of human TH1 and TH2 cells | Q40414078 |
| | Perinatal inflammatory cytokine challenge results in distinct neurobehavioral alterations in rats: implication in psychiatric disorders of developmental origin | Q40492047 |
| | Effects of clozapine on plasma cytokine and soluble cytokine receptor levels | Q40663250 |
| | Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families | Q40722387 |
| | Cognitive and behavioral precursors of schizophrenia. | Q40792725 |
| | Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders | Q40864089 |
| | Genetics of infectious disease resistance | Q41099943 |
| | Modulation of T-cell cytokine secretion by accessory cell-derived products. | Q41166400 |
| | Schizophrenia and B-lymphocyte alteration--a hypothesis | Q41563508 |
| | Antibodies to the human 60 kDa heat-shock protein in patients with schizophrenia | Q41603685 |
| | Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis | Q41709477 |
| | Prostaglandin-mediated control of rat brain kynurenic acid synthesis--opposite actions by COX-1 and COX-2 isoforms | Q42166234 |
| | Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia? | Q42554797 |
| | Relationship between in utero exposure to influenza epidemics and risk of schizophrenia in Denmark | Q42642954 |
| | The accessory function of murine intercellular adhesion molecule-1 in T lymphocyte activation. Contributions of adhesion and co-activation | Q42807079 |
| | Significant frequency deviation of the class I polymorphism HLA-A10 in schizophrenic patients | Q43074283 |
| | Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons | Q43673567 |
| | Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection | Q43718624 |
| | Increased cortical kynurenate content in schizophrenia | Q43766055 |
| | Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia | Q43783037 |
| | Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid | Q43975284 |
| | Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia | Q44013100 |
| | Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat. | Q44059916 |
| | L-4-chlorokynurenine attenuates kainate-induced seizures and lesions in the rat. | Q44214571 |
| | Kynurenate production by cultured human astrocytes | Q44286634 |
| | Cerebral tryptophan-2,3-dioxygenase (pyrrolase) and its induction in rat brain | Q48560764 |
| | Aspects of normal cerebrospinal fluid circulation and circumventricular organs | Q48588645 |
| | Species heterogeneity between gerbils and rats: quinolinate production by microglia and astrocytes and accumulations in response to ischemic brain injury and systemic immune activation | Q48604730 |
| | IL-12 production by central nervous system microglia is inhibited by astrocytes | Q48637135 |
| | Lipopolysaccharide-induced IL-12 expression in the central nervous system and cultured astrocytes and microglia. | Q48653292 |
| | The role of cytokines in mediating effects of prenatal infection on the fetus: implications for schizophrenia | Q48764514 |
| | (R,S)-3,4-dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats | Q48859376 |
| | Kynurenine disposition in blood and brain of mice: effects of selective inhibitors of kynurenine hydroxylase and of kynureninase | Q48957545 |
| | Cytokines production in chronic schizophrenia patients with or without paranoid behaviour. | Q50860584 |
| | Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. | Q51000957 |
| | Decreased T cellular immune response in schizophrenic patients. | Q51282803 |
| | No association between the G308A polymorphism of the tumor necrosis factor-alpha gene and schizophrenia. | Q51952057 |
| | Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. | Q51981236 |
| | Association between prenatal exposure to poliovirus infection and adult schizophrenia. | Q51983381 |
| | Support for genetic variation in neuregulin 1 and susceptibility to schizophrenia. | Q53654455 |
| | Association between −G308A tumor necrosis factor alpha gene polymorphism and schizophrenia | Q56767241 |
| | In vivo immunomodulatory effects of clozapine in schizophrenia | Q56767408 |
| | Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizers | Q56767487 |
| | Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease | Q57260160 |
| | Exposure to Prenatal and Childhood Infections and the Risk of Schizophrenia | Q57517104 |
| | Childhood central nervous system infections and risk for schizophrenia | Q59117655 |
| | A genome-wide autosomal screen for schizophrenia susceptibility loci in 71 families with affected siblings: support for loci on chromosome 10p and 6 | Q59791687 |
| | Smoking and schizophrenia | Q67524559 |
| | Cellular immunity in schizophrenic patients before and during neuroleptic treatment | Q68312612 |
| | Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes | Q69050686 |
| | Effects of short-term administration of antipsychotic drugs on lymphocyte subsets in schizophrenic patients | Q69375051 |
| | Aberrant T cell-mediated immunity in untreated schizophrenic patients: deficient interleukin-2 production | Q69498800 |
| | Elevated plasma prostaglandin E2 levels in schizophrenia | Q69653588 |
| | Influence of therapy on antibody-formation | Q70545797 |
| | Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats | Q71300221 |
| | Fibrin degradation products in post mortem brain tissue of schizophrenics: a possible marker for underlying inflammatory processes | Q71493287 |
| | Cytokine production in drug-free and neuroleptic-treated schizophrenic patients | Q71578154 |
| | Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial | Q71607775 |
| | Increased soluble endothelial adhesion molecules in rheumatoid arthritis correlate with circulating cytokines and depletion of CD45RO+ T-lymphocytes from blood stream | Q71681156 |
| | Production of interferons and lymphokines in leukocyte cultures of patients with schizophrenia | Q71704434 |
| | Evaluation of a susceptibility gene for schizophrenia on chromosome 6p by multipoint affected sib–pair linkage analysis | Q71794036 |
| | Production of cytokines in acute schizophrenic psychosis | Q71871879 |
| | Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. The influence of age at onset and negative symptoms | Q71950337 |
| | An analysis of lymphocyte subpopulations in schizophrenic patients | Q72117119 |
| | Immunoglobulin and albumin content of cerebrospinal fluid in schizophrenic patients: relationship to negative symptomatology | Q72277316 |
| | The concept of substrate-close basic symptoms and its significance for the theory and therapy of schizophrenic diseases | Q72551739 |
| | Increased serum IgE in schizophrenic patients who responded poorly to neuroleptic treatment | Q72679099 |
| | Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness | Q72679203 |
| | Interleukin-1 alpha in blood has direct access to cortical brain cells | Q72744100 |
| | Is there a balance between microglia and astrocytes in regulating Th1/Th2-cell responses and neuropathologies? | Q73102572 |
| | Activated human microglia produce the excitotoxin quinolinic acid | Q73175992 |
| P433 | issue | 2 | |
| P921 | main subject | inflammation | Q101991 |
| | schizophrenia | Q41112 |
| P304 | page(s) | 131-148 | |
| P577 | publication date | 2006-10-01 | |
| P1433 | published in | Neurotoxicity Research | Q15764278 |
| P1476 | title | Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission | |
| P478 | volume | 10 | |